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Abstract
The present studywas designed to investigate the eﬀect of pharmacological inhibition of endocannabinoid
degradation on behavioural actions of the dopamine D2/D3 receptor agonist quinpirole in male C57Bl/6J
mice. In addition, we studied the eﬀects of endocannabinoid degradation inhibition on both cocaine-
induced psychomotor activation and behavioural sensitization. We analysed the eﬀects of inhibition of
the two main endocannabinoid degradation enzymes : fatty acid amide hydrolase (FAAH), using
inhibitor URB597 (1 mg/kg) ; monoacylglycerol lipase (MAGL), using inhibitor URB602 (10 mg/kg).
Administration of quinpirole (1 mg/kg) caused a temporal biphasic response characterized by a ﬁrst
phase of immobility (0–50 min), followed by enhanced locomotion (next 70 min) that was associated with
the introduction of stereotyped behaviours (stereotyped jumping and rearing). Pretreatment with both
endocannabinoid degradation inhibitors did not aﬀect the hypoactivity actions of quinpirole. However,
this pretreatment resulted in a marked decrease in quinpirole-induced locomotion and stereotyped
behaviours. Administration of FAAH or MAGL inhibitors did not attenuate the acute eﬀects of cocaine.
Furthermore, these inhibitors did not impair the acquisition of cocaine-induced behavioural sensitization
or the expression of cocaine-induced conditioned locomotion. Only MAGL inhibition attenuated the ex-
pression of an already acquired cocaine-induced behavioural sensitization. These results suggest that
pharmacological inhibition of endocannabinoid degradation might exert a negative feedback on D2/D3
receptor-mediated hyperactivity. This ﬁnding might be relevant for therapeutic approaches for either
psychomotor disorders (dyskinesia, corea) or disorganized behaviours associated with dopamine-
mediated hyperactivity.
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Introduction
The endocannabinoids anandamide (AEA) and 2-
arachidonoylglycerol (2-AG) are retrograde messen-
gers that regulate a variety of brain functions through
stimulation of cannabinoid receptors type 1 and 2 (CB1
and CB2 ; Placzek et al. 2008; Wang & Ueda, 2008). The
CB1 receptor is highly expressed on axon terminals of
glutamatergic and c-aminobutyric acid (GABA)ergic
projecting neurons, through which the endogenous
cannabinoid system controls neurotransmitter release
and synaptic plasticity (Adermark & Lovinger, 2007 ;
Adermark et al. 2009; Gerdeman & Lovinger, 2001 ;
Piomelli, 2003). The endocannabinoid system (ECS) is
mainly involved in motor, motivational, emotional
and cognitive processes (Giuﬀrida et al. 1999, 2004 ;
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Luchicchi et al. 2010; Rasmussen et al. 2009; Rodriguez
de Fonseca et al. 1998; Solinas et al. 2007). In addition,
the ECS regulates dopamine-mediated behaviours
(Rodriguez de Fonseca et al. 2001). This role is related
to its anatomical presence in basal ganglia circuits
(Martin et al. 2008; Rodriguez de Fonseca et al. 1998,
2001 ; Solinas et al. 2008).
Due to the presence of the ECS in brain dopami-
nergic circuits, much work has been performed to
clarify its role in brain reward processes (Gardner,
2005). For instance, pharmacological modulation of
the ECS appears to regulate dopamine-mediated
rewarding eﬀects of alcohol, cannabis, opioids and
psychostimulants (Colombo et al. 2005; de Vries et al.
2001; Ledent et al. 1999; Maldonado & Rodriguez de
Fonseca, 2002 ; Scherma et al. 2008). However, less
work has been performed regarding behavioural
consequences of endocannabinoid signalling modu-
lation in motor control. Some evidence suggests that
regulation of psychomotor output might depend on
the interaction between the endocannabinoid and the
dopaminergic systems in both the basal ganglia and
the mesolimbic reward system (Giuﬀrida & Piomelli,
2000 ; Glass et al. 1997).
Analysis of the role of the ECS in dopamine-
mediated behaviours suggests that endocannabinoids
exert a complex regulatory role in both dopamine-
releasing and dopamine receptor-expressing neurons.
For instance, activation of the CB1 receptor induces
dopamine release in rodents and humans (Bossong
et al. 2009; Ng Cheong Ton et al. 1988; O’Neill et al.
2009). This eﬀect is thought to be mediated by the re-
inforcing properties of natural cannabinoids (Gardner,
2005). Conversely, activation of dopamine D2/D3 re-
ceptors stimulates production of the endocannabinoid
AEA in the dorsal striatum (Giuﬀrida et al. 1999). In
this situation, the ECS would be acting as an inhibitory
feedback mechanism that counteracts the dopamine-
induced facilitation of motor activity (Beltramo et al.
2000). Supporting this hypothesis, previous reports
show that the CB1 receptor agonist WIN 55,212-2 is
able to ameliorate dyskinesias (Ferrer et al. 2003).
Conversely, the CB1 receptor antagonist SR141716A
aggravates the stereotypies induced by pharmaco-
logical over-activation of dopamine receptors (Ferrer
et al. 2007). Moreover, desensitization of CB1 receptors
induced by D9-tetrahydrocannabinol administration
facilitates dopamine-mediated behaviours (Gorriti
et al. 1999, 2005).
Although the role of dopamine D2/D3 receptors as
activators of endocannabinoid release is well known
(Giuﬀrida et al. 1999), the eﬀects of psychostimulants
on the activation of the ECS are much less understood.
Among psychostimulants, cocaine is a monoamine
reuptake inhibitor that interferes with the uptake of
dopamine, noradrenaline and serotonin (Ritz et al.
1990). Cocaine also induces an augmented motor re-
sponse after repeated administration (sensitization;
Blanco et al. 2012a, b). Acute cocaine administration
increases AEA levels in the striatum (Arnold, 2005).
This eﬀect is mediated by dopaminergic D2-like
receptors (Arnold, 2005). However, as in the case of
dopamine D2/D3 receptor agonists, there is no clear
evidence that the increase of endocannabinoids in-
duced by cocaine also acts as an inhibitory feedback
signal for cocaine-induced stimulation. It is important
to note that the eﬀects of cocaine, including reinforcing
eﬀects, can be mediated by non-dopaminergic neurons
through interactions with other neurotransmitter sys-
tems, such as the serotoninergic system (Hnasko et al.
2007).
From the studies described above, we can hypoth-
esize that endocannabinoids generated by dopamine
D2/D3 receptor activation serve as counter-regulatory
signals that limit behavioural over-activation. To con-
ﬁrm this hypothesis, we performed studies with
inhibitors of endocannabinoid degradation. AEA and
2-AG are generated by cells on demand through
stimulus-dependent cleavage of membrane phospho-
lipid precursor and undergo rapid biological deacti-
vation after release (di Marzo et al. 1994; Stella et al.
1997). Both AEA and 2-AG are degraded and elim-
inated through enzymatic hydrolysis by fatty acid
amide hydrolase (FAAH) and monoacylglycerol
lipase (MAGL), respectively (Cravatt et al. 1996, 2001).
Blockage of this degradation will result in enhanced
availability of endocannabinoids, which may counter-
act quinpirole-induced locomotion/stereotypy and
cocaine-induced sensitization. Thus, the main goals of
the present study were as follows : (a) to characterize
locomotor activity and stereotypic behaviours induced
by the dopamine D2/D3 receptor agonist quinpirole in
a mouse model ; (b) to evaluate the eﬀects of FAAH
and MAGL inhibition on quinpirole-induced behav-
iours ; (c) to assess the eﬀects of FAAH and MAGL
inhibition on horizontal locomotion, conditioned
locomotion and behavioural sensitization induced by
cocaine.
Method
Animals
C57B1/6J adult male mice (Charles River, Spain) were
maintained in controlled housing conditions (12 h
light/dark cycle, lights on 08:00 hours ; temperature :
20¡2 xC; humidity : 40¡5%) with food and water
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ad libitum at the University of Malaga’s vivarium. The
experimental procedures were in accordance with
European Communities Council Directives 86/609/
EU, 98/81/CEE, 2003/65/EC and Commission
Recommendation 2007/526/EC.
Drugs
The dopamine D2/D3 receptor agonist quinpirole
hydrochloride (QNP; Tocris Cookson Ltd, UK) was
dissolved in a solution of DMSO, Tween 80 and sterile
saline (1 :1 :8, Veh) and administered subcutaneously
at doses of 0.05, 0.1 and 1 mg/kg. Selective inhibitors
of FAAH [URB597 [3k-(aminocarbonyl)[1,1k-biphenyl]-
3-yl)-cyclohexylcarbamate)] and MAGL [URB602
([1,1k-biphenyl]-3-yl-carbamic acid, cyclohexyl ester) ;
Cayman, USA] were dissolved in Veh and injected i.p.
at doses of 1 mg/kg (URB597) or 10 mg/kg (URB602).
Cocaine hydrochloride (Sigma-Aldrich, Spain) was
dissolved in a sterile saline solution and administered
i.p. at doses of 10 or 20 mg/kg. All of the drugs were
injected in a volume of 1 ml/kg.
Apparatus and general procedures
Animals were handled and habituated to injection pro-
cedures once per day for 5 d. All of the experiments
were carried out between 08:00 and 20:00 hours. Each
day, the animals were acclimatized to the experimen-
tal room for 30 min. Performance in the open ﬁeld
(OF) was recorded by a computer-based video track-
ing system (Smart v2.51 ; Panlab, Spain). Stereotyped
behaviours were directly observed by placing the ani-
mals in transparent glass observational cylinders
(OCs). The maximum light intensity in the centre of
the OF and inside the OC was 100 lux. All of the ap-
paratuses were cleaned with a 70% ethanol solution.
Open ﬁeld
Four OFs (50r50r50 cm; Panlab) with grey back-
grounds were used. Animals were placed in the centre
of each arena and their behaviour was recorded for 30
or 120 min. Horizontal locomotion was measured as
the total distance travelled (cm). The immobility vari-
able was evaluated as the total time of immobility (s)
using a detection ﬁlter (detection range less than
10 cm/s). Because analysis of locomotion and time
spent in the centre of the OF is considered an index of
anxiety in cannabinoid studies (Long et al. 2010;
Thiemann et al. 2009), we also registered the distance
travelled in periphery and centre area. The centre of
the OF was deﬁned as a square of 30r30 cm. A mouse
was considered to be in the central area when its four
paws were in it.
Observational cylinders
Quantiﬁcation of stereotyped activity was performed
by direct observation of the animals after they were
placed in the glass transparent OCs (60 cm heightr
12 cm diameter). Eight cylinders were attached to the
original base of the OF in the perimeter of the arena.
Clean bedding material was added after each animal
test. Animals were injected with Veh or QNP and/or
the inhibitors of endocannabinoid degradation and
placed in the cylinders. Evaluation of stereotyped
behaviours (such as jumping, rearing and grooming)
was performed by trained observers blind to the ex-
perimental conditions. Quantiﬁcation was performed
at 10 min time intervals for a total time of 120 min
post-injection.
Behavioural procedures
We performed a total of ﬁve experiments. In expt 1, we
evaluated the eﬀect of QNP administration on loco-
motion/immobility behaviour in the OF. In expt 2, we
analysed stereotyped behaviours in the OC. In expt 3,
we assessed the eﬀects of FAAH andMAGL inhibitors
on anxiety, habituation, locomotion activity and stereo-
typed behaviours in the OF and OC. In expt 4, we
analysed the eﬀects of FAAH and MAGL inhibitors on
QNP-induced locomotion and stereotyped behaviours
in the OF and OC. Finally, we evaluated the eﬀects
of FAAH and MAGL inhibitors in acute/repeated
cocaine administration, conditioned locomotion and
behavioural sensitization in the OF (expt 5).
Evaluation of locomotion and stereotyped
behaviours after administration of QNP and/or
inhibitors of FAAH/MAGL in the OF and OC
Animals were injected with Veh or diﬀerent single
doses of QNP (expt 1 and expt 2), URB597 or URB602
(expt 3) or were co-administered QNP+URB597
or QNP+URB602 (expt 4). When drugs were co-
administered, URB597 and URB602 were injected
30 min before QNP.
Evaluation of FAAH/MAGL inhibitors on acute/
repeated cocaine administration, conditioned
locomotion and behavioural sensitization in the OF
Animals received a single i.p. injection of Veh, cocaine,
URB597, URB602, URB597+cocaine or URB602+
cocaine in the diﬀerent phases of the experiment
(expt 5). Brieﬂy, mice were exposed to acute or re-
peated cocaine administration (20 mg/kg) for ﬁve
consecutive days. One half of the animals were treated
with cocaine, cocaine+URB597 or cocaine+URB602.
The other half of the animals were treated with Veh,
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URB597 or URB602. After the 5 d, mice rested in their
home cages without drugs for another 5 d. Twenty-
four hours later, we evaluated the conditioned loco-
motion response after administration of Veh, URB597
or URB602. On the last day, we tested the behavioural
sensitization by injection of a prime dose of cocaine
(10 mg/kg), cocaine (10 mg/kg)+URB597 or cocaine
(10 mg/kg)+URB602. Using two other groups of ani-
mals, we also evaluated the eﬀects of acute adminis-
tration of URB597 and URB602 on an already acquired
conditioned locomotion and cocaine sensitization re-
sponse. During all of these phases, the animals were
evaluated in the OF immediately after the drug or
Veh injections to measure the distance travelled over
30 min. Conditioned locomotion and behavioural
sensitization protocols used in this study are based
on Pavlovian conditioning. Classical Pavlovian con-
ditioning is a basic process of associative learning that
allows an animal to predict and adapt to future events
based on previous experience. Conditional learning
involves the association of a neutral stimulus with
an unconditional stimulus (UCS) that elicits an un-
conditional response (UCR). After repeated pairing,
the neutral stimulus becomes a conditional stimulus
(CS) that induces a conditional response (CR) similar
to the original UCR. In our study, the psychostimulant
cocaine (UCS) produces an increased locomotor re-
sponse (UCR). Repeated pairing of drug adminis-
tration (daily cocaine injections as UCS) with a speciﬁc
context (OF as CS) typically leads to an enhanced
locomotor response (conditioned locomotion as CR)
when mice are re-exposed without cocaine in the OF.
In addition, this conditioned motor-stimulant re-
sponse is exponentially increased by a single injection
of a prime dose of cocaine (behavioural sensitization).
Statistical analysis
Results were expressed as the mean¡S.E.M. Data
were analysed by one-, two- or three-way analysis of
variance (ANOVA) tests with or without repeated
measures, followed by a post-hoc Tukey–Kramer test.
The Greenhouse–Geisser’s correction was employed
when appropriate. A probability was considered to be
signiﬁcant at f5%. Statistical analyses were per-
formed with SPSS 15.0 (SPSS Inc., USA).
Results
Hyperactivity and immobility induced by acute
treatment with quinpirole in C57/Bl6J mice
Mice were injected with QNP (0.1 or 1 mg/kg) or Veh
and exposed to the OF for 2 h. Distance travelled was
measured in 10 min time intervals. ANOVA showed
that the eﬀects of treatment, time interval and the
interaction were signiﬁcant (F2,27=21.87, p<0.001;
F5.28,142.66=8.40, p<0.001; F10.56,142.66=19.22, p<0.001).
ANOVAs performed on each time interval showed
that the eﬀect of treatment was signiﬁcant in the
ﬁrst eight time intervals (F2,27=203.94, p<0.001;
F2,27=223.61, p<0.001; F2,27=86.32, p<0.001; F2,27=
35.93, p<0.001 ; F2,27=17.09, p<0.001; F2,27=6.96,
p<0.001 ; F2,27=20.31, p<0.001; F2,27=11.69, p<0.001).
Post-hoc tests revealed that mice injected with both
doses of QNP travelled signiﬁcantly shorter distances
than Veh-injectedmice during the ﬁrst 50 min (Fig. 1a).
In contrast, mice injected with 1 mg/kg QNP travelled
a signiﬁcantly longer distance compared to other
groups at 50–80 min (Fig. 1a). When locomotion was
expressed as a percentage of the distance travelled by
Veh-injected mice, the eﬀects of treatment, time inter-
val and the interaction were signiﬁcant (F1,18=5.43,
p=0.032 ; F4.37,78.71=46.56, p<0.001 ; F4.37,78.71=10.34,
p<0.001). Post-hoc tests revealed that, during the ﬁrst
30 min, mice injected with 1 mg/kg QNP displayed a
signiﬁcantly lower percentage of distance travelled
than mice injected with 0.1 mg/kg QNP. These data
show that both groups had lower levels of locomotion
in comparison to the Veh group (Fig. 1b). In contrast,
mice injected with 1 mg/kg QNP showed a signiﬁ-
cantly higher percentage of distance travelled when
compared to mice injected with 0.1 mg/kg QNP or
Veh at 50–80 min (Fig. 1b). Furthermore, when data
were collapsed into 0–50 min and 50–120 min groups,
ANOVAs revealed signiﬁcant diﬀerences (F2,27=
270.28, p<0.001 ; F2,27=19.37, p<0.001). Furthermore,
post-hoc tests indicated that during the ﬁrst 50 min
both groups injected with QNP travelled a signiﬁ-
cantly decreased distance when compared to the Veh
group. This eﬀect occurred in a dose-dependent man-
ner (Fig. 1c). From 50 to 120 min, the group injected
with the highest dose of QNP displayed a signiﬁcantly
longer distance travelled in comparison with the other
groups (Fig. 1d). Regarding immobility time, ANOVA
showed that the eﬀects of treatment, time interval and
the interaction were signiﬁcant (F2,27=16.54, p<0.001;
F3.51,94.80=6.79, p<0.001; F7.02,94.80=10.78, p<0.001).
ANOVAs showed that the eﬀect of treatment was
signiﬁcant in the ﬁrst 50 min and from 60 to 80 min
(0–10 min: F2,27=461.37, p<0.001 ; 10–20 min: F2,27=
377.08, p<0.001 ; 20–30 min: F2,27=311.39, p<0.001;
30–40 min: F2,27=28.94, p<0.001; 40–50 min:
F2,27=21.62, p<0.001; 60–70 min: F2,27=5.27, p=0.012;
70–80 min: F2,27=3.79, p=0.036). Post-hoc tests in-
dicated that, during the ﬁrst 50 min, mice injected with
both doses of QNP spent a longer time immobilized
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compared to the Veh group. This eﬀect also occurred
in a dose-dependent manner (Fig. 1e). From 60 to
80 min, mice injected with the highest dose of QNP
had a similar immobility time compared to the Veh
group (Fig. 1e). ANOVA performed on collapsed data
from 0 to 50 min were signiﬁcant (F2,27=226.48,
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Fig. 1. Eﬀects of acute treatment with the dopamine D2/D3 receptor agonist quinpirole hydrochloride (QNP) on locomotion
in C57/BI6J mice : characterization of a biphasic response evaluated in the open ﬁeld (OF). (a) Locomotor activity after acute
QNP administration (*** p<0.001, ** p<0.01 and * p<0.05 compared to all other groups ; # p<0.05 compared to QNP 1 mg/kg) ;
(b) percentage change in locomotion after acute QNP administration (*** p<0.001 and ** p<0.01 compared to the other group) ;
(c) eﬀect of QNP-induced hypolocomotion for the ﬁrst 50 min [*** p<0.001 compared to vehicle (Veh) control group; ## p<0.01
compared to QNP 0.1 mg/kg] ; (d) the enhanced locomotion for the last 70 min after QNP administration (*** p<0.001
compared to QNP 0.1 mg/kg and Veh control groups) ; (e) immobility response after acute QNP administration (*** p<0.001,
+++ p<0.001 and + p<0.05 compared to Veh control group; ### p<0.001, ## p<0.01 and # p<0.05 compared to QNP
0.1 mg/kg) ; ( f ) eﬀect of QNP-induced immobility for the ﬁrst 60 min (*** p<0.001 compared to Veh control group; ### p<0.001
compared to QNP 0.1 mg/kg). Values represent the mean¡S.E.M. (n=10 per group).
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p<0.001) and post-hoc tests conﬁrmed that both doses
of QNP enhanced immobility (Fig. 1 f).
Stereotypic behaviours elicited by acute treatment
with quinpirole in C57/Bl6J mice
Stereotypic behaviours (jumping, rearing and groom-
ing) were measured during the 2 h after Veh or QNP
injections in the OC. Regarding jumping, ANOVA
performed between 60 and 110 min indicated that the
eﬀects of treatment, time interval and the interaction
were signiﬁcant (F3,36=15.04, p<0.001 ; F3.07,110.53=5.31,
p<0.001 ; F9.21,110.53=3.25, p<0.001). ANOVAs showed
that the eﬀect of treatment was signiﬁcant in all of the
time intervals except the ﬁrst (60–70 min: F3,36=2.77,
p=n.s. ; 70–80 min: F3,36=7.57, p<0.001 ; 80–90 min:
F3,36=18.88, p<0.001 ; 90–100 min: F3,36=7.45, p<
0.001 ; 100–110 min: F3,36=3.80, p=0.018). Post-hoc
tests revealed that from 70 to 110 min mice injected
with the highest dose of QNP displayed a signiﬁcantly
higher number of jumps compared to the other groups
(Fig. 2a). When an ANOVA was conducted on the
total number of jumps between 70 and 110 min, the
eﬀect of treatment was signiﬁcant (F3,36=15.44,
p<0.001). Post-hoc tests showed that an injection of
1 mg/kg QNP signiﬁcantly increased the number
of jumps (Fig. 2b). Concerning rearing behaviour,
ANOVA performed between 50 and 90 min indicated
that the eﬀect of treatment and the treatmentrtime
interval interaction were signiﬁcant (F3,36=4.70,
p<0.01 ; F9,108=4.83, p<0.001). ANOVAs showed that
the eﬀect of treatment was signiﬁcant in the 60–70
and 70–80 min time intervals (F3,36=9.90, p<0.001;
F3,36=10.65, p<0.001). Post-hoc tests revealed that from
60 to 80 min mice injected with 1 mg/kg QNP dis-
played a signiﬁcantly higher number of rearing in
comparison to the other groups (Fig. 2c). ANOVA
performed on collapsed data from 60 to 80 min
was signiﬁcant (F3,36=15.94, p<0.001). Post-hoc tests
showed that an injection of 1 mg/kg QNP signiﬁcantly
increased the number of rearing (Fig. 2d). Finally,
grooming behaviour was not signiﬁcantly aﬀected by
QNP administration (Fig. 2e, f).
FAAH and MAGL inhibitors did not modify
locomotion, anxiety, habituation or stereotypic
behaviours in C57/Bl6J mice
To evaluate the eﬀects of FAAH and MAGL inhibitors
on horizontal locomotion, anxiety and habituation,
mice were injected with URB597 (1 mg/kg), URB602
(10 mg/kg) or Veh and tested in two OF sessions with
a 24 h inter-session interval. Locomotion was evalu-
ated during the whole duration of the ﬁrst OF
session. ANOVA indicated that neither the eﬀect of
treatment (Fig. 3b) nor the interaction was signiﬁcant
(F2,33<1, p=n.s. ; F10.384,171.34<1, p=n.s.). However, the
eﬀect of time interval was signiﬁcant (F5.192,171.34=7.88,
p<0.001). These results suggest that all of the groups
showed the same levels of locomotor activity.
Furthermore, locomotor activity in the groups pro-
gressively decreased in the same manner over time
(Fig. 3a). To determine if treatment with FAAH and
MAGL inhibitors had any eﬀect on anxiety levels and
inter-session habituation, we measured the distance
travelled by mice in the periphery and the central zone
of the OF during the ﬁrst 30 min of both sessions. A
three-way ANOVA, with treatment (Veh or URB597
or URB602) as between-subject factor and zone and
day as within-subject factors, indicated that the eﬀect
of treatment was not signiﬁcant (F2,33<1, p=n.s.).
However, the eﬀects of zone and day were signiﬁcant
(F1,33=954.70, p<0.001; F1,33=59.83, p<0.001). Post-hoc
tests showed that all of the groups displayed signiﬁ-
cantly higher levels of locomotion in the periphery
zone of the OF when compared to the central zone
(Fig. 3c). Additionally, during the second OF session,
all of the groups showed signiﬁcantly lower levels of
locomotion in comparison to the ﬁrst session (Fig. 3d).
Finally, to study whether FAAH andMAGL inhibitors
had any eﬀect on stereotypic behaviours, another
subset of mice was injected with URB597 (1 mg/kg),
URB602 (10 mg/kg) or Veh and evaluated in the OC
over 2 h. We quantiﬁed stereotypic behaviours at the
speciﬁc time intervals where QNP signiﬁcantly in-
creased locomotion and stereotypic behaviours
(Figs. 1a–f, 2a–f). ANOVAs showed that neither group
diﬀered in the number of jumping, rearing or groom-
ing behaviours (F2,27<1, p=n.s. ; F2,27=1.64, p=n.s. ;
F2,27<1, p=n.s.) (Fig. 3e–g). These results lead us
to conclude that treatment with FAAH or MAGL
inhibitors did not modify locomotor activity,
anxiety, habituation or stereotypic behaviours in
C57/Bl6J mice.
Co-administration of FAAH or MAGL inhibitors
and quinpirole counteracts quinpirole-induced
hyperactivity and stereotypic behaviour
Groups of mice were injected with Veh, QNP
(1 mg/kg), QNP and URB597 (1 mg/kg) or QNP and
URB602 (10 mg/kg) and evaluated in the OF and OC.
In the ﬁrst 50–70 min post-injection, FAAH and
MAGL inhibitors did not reverse nor potentiate the
motor depressing eﬀects of QNP (distance travelled in
the OF in the ﬁrst 50 min: F3,44=140.76, p<0.001 ; rear-
ing in the OC in the ﬁrst 60 min: F3,44=30.51, p<0.001)
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(Fig. 4a, c). Number of jumps did not diﬀer at this
early phase of QNP action (F3,44<1, p=n.s. ; Fig. 4b).
However, inhibition of endocannabinoid degradation
did suppress the enhanced locomotion and stereotypic
activity that appears in the second phase of QNP
action (distance travelled in the OF: F3,44=15.71,
p<0.001 ; jumps and rearing in the OC: F3,44=13.98,
p<0.001 ; F3,44=10.46, p<0.001; Fig. 4d–f). Post-hoc
tests conﬁrmed that mice injected with QNP travelled
a longer distance and displayed a higher number of
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jumps and rearing in comparison to the other
groups (Fig. 4d–f). Furthermore, groups injected with
QNP+URB597 or QNP+URB602 did not diﬀer
from Veh-injected mice. These results suggest that co-
administration of FAAH or MAGL inhibitors with
QNP reversed QNP-induced hyperactivity and
stereotypic behaviours.
Eﬀects of FAAH and MAGL inhibitors on
cocaine-induced locomotion and behavioural
sensitization
We conducted a series of experiments to study the
inﬂuence of FAAH and MAGL inhibitors on: (a) the
locomotion response elicited by acute cocaine admin-
istration ; (b) the acquisition of cocaine-induced sensi-
tization ; (c) the expression of conditioned locomotion;
(d) the expression of cocaine sensitization. In an initial
experiment, a group ofmice were injectedwith a single
dose of cocaine (20 mg/kg), URB597 (1 mg/kg),
URB602 (10 mg/kg), Veh or cocaine with URB597
or URB602. ANOVA indicated that the eﬀect of treat-
ment was signiﬁcant (F5,42=39.10, p<0.001). Post-hoc
tests showed that the distance travelled by mice in-
jected with cocaine alone or injected with cocaine and
URB597 or URB602 was signiﬁcantly longer in com-
parison to the groups injected with Veh, URB597
or URB602 (Fig. 5a). This result suggests that FAAH
and MAGL inhibitors did not aﬀect the acute cocaine-
induced locomotion response.
In a second experiment, another cohort of animals
were injected once per day for ﬁve consecutive days
with cocaine (20 mg/kg), URB597 (1 mg/kg), URB602
(10 mg/kg), Veh or cocaine with URB597 or URB602.
ANOVA showed that the eﬀects of treatment, day and
the interaction were signiﬁcant (F5,54=63.72, p<0.001;
F3.06,165.30=31.36, p<0.001 ; F15.30,165.30=3.38, p<0.001).
ANOVAs performed on each day were also all sig-
niﬁcant (day 1: F5,54=11.30, p<0.001 ; day 2: F5,54=
56.91, p<0.001; day 3: F5,54=31.88, p<0.001 ; day 4:
F5,54=25.21, p<0.001 ; day 5: F5,54=41.07, p<0.001).
Post-hoc tests revealed that the distance travelled
by mice injected with cocaine alone or injected with
URB597 or URB602 and cocaine was signiﬁcantly
longer than distance travelled by mice injected with
URB597, URB602 or Veh (Fig. 5b). This result suggests
that the endocannabinoid degradation inhibitors
did not produce any eﬀect on cocaine Pavlovian con-
ditioning. Next, mice were left undisturbed for ﬁve
consecutive days. Twenty-four hours later, groups
previously conditioned with cocaine were injected
with Veh and exposed to the OF to evaluate the con-
ditioned locomotion response. The next day, mice in
the same groups were injected with a prime dose
of cocaine (10 mg/kg). Cocaine sensitization was
evaluated by comparing the distance travelled by
the mice after injection of the prime dose of cocaine
to the distance travelled on the previous day (con-
ditioned locomotion). The ANOVA indicated that the
eﬀects of pretreatment (cocaine, cocaine+URB597
or cocaine+URB602) and the pretreatmentrprotocol
interaction (conditioned locomotion or cocaine sensi-
tization) were not signiﬁcant (F2,27<1 in both cases). In
contrast, the eﬀect of the protocol was signiﬁcant
(F1,27=121,02, p<0.001). Post-hoc tests showed that the
three groups travelled signiﬁcantly longer distances
during the cocaine sensitization session when com-
pared to the conditioned locomotion session (Fig. 5c).
These results suggest that administration of FAAH
and MAGL inhibitors during cocaine conditioning did
not aﬀect the development of conditioned locomotion
and cocaine sensitization.
Additionally, we conducted another experiment to
study the eﬀects of acute administration of FAAH and
MAGL inhibitors on the conditioned locomotion and
cocaine sensitization response. Mice were conditioned
with cocaine (20 mg/kg) or treated with Veh over
ﬁve consecutive days (data not shown). Five days
after ﬁnishing the conditioning protocol, a subset of
mice were treated with Veh, URB597 (1 mg/kg) or
URB602 (10 mg/kg) and exposed to the OF. ANOVA
(F3,36=8.07, p<0.001) followed by post-hoc tests in-
dicated that mice conditioned with cocaine travelled a
signiﬁcantly longer distance when compared to mice
previously treated with Veh (Fig. 5d). Moreover,
mice previously conditioned with cocaine and treated
with an acute injection of URB597 or URB602 also
travelled a signiﬁcantly longer distance than mice
Fig. 3. Eﬀects of administration of either a fatty acid amide hydrolase (FAAH) inhibitor (URB597) or a monoacylglycerol lipase
(MAGL) inhibitor (URB602), on locomotion, anxiety, habituation and stereotypic behaviours in male mice. (a, b ) Locomotion
in the open ﬁeld (OF; A, at time-intervals ; B, data accumulated) ; (c) exploration of peripheral vs. central zones measured in
the OF (*** p<0.001 compared to peripheral zone) ; (d) the environmental novelty (day 1) vs. familiarity (day 2) response in the
development of habituation to the OF (*** p<0.001, **p<0.01 compared to day 1) ; (e) stereotypic jumping, ( f ) rearing and
(g) grooming behaviours measured in the observational cylinder. All of these behaviours were evaluated after acute
administration of vehicle (Veh), FAAH or MAGL inhibitors (a–g). Values represent the mean¡S.E.M. (n=10–12 per group).
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previously treated with Veh (Fig. 5d). This suggests
that acute treatment with endocannabinoid degra-
dation inhibitors did not modify the conditioned
locomotion response. Finally, another subset of
animals previously conditioned with cocaine received
a prime injection of cocaine (10 mg/kg) with or with-
out an acute injection of URB597 or URB602. Mice
previously treated with Veh received an acute injec-
tion of cocaine or Veh. ANOVA (F4,45=24.93, p<0.001)
followed by post-hoc tests revealed that mice that
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Fig. 4. Eﬀects of pre-treatment with either a fatty acid amide hydrolase inhibitor (URB597) or a monoacylglycerol lipase inhibitor
(URB602) on quinpirole hydrochloride (QNP)-induced behaviours in mice. The hypoactivity induced by QNP in the ﬁrst phase
was not potentiated by these inhibitors. This is reﬂected in the data on (a) locomotion (0–50 min), (b) jumping (0–70 min) and
(c) rearing (0–60 min). However, both the hyperactivity and the appearance of stereotyped behaviours induced by QNP in the
second phase (60–110 min post-injection) were attenuated by administration of both inhibitors. This is reﬂected in (d) the
reduction of locomotion (60–90 min), (e) attenuation of jumping (70–110 min) and (f) reduction of rearing (60–80 min).
*** p<0.001 compared to all other groups. Values represent the mean¡S.E.M. (n=12 per group).
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Fig. 5. Eﬀects of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitors on cocaine-induced
activity in the open ﬁeld. (a) The eﬀect of co-administration of FAAH andMAGL inhibitors in acute cocaine-induced locomotion
(*** p<0.001 compared to groups without acute cocaine injection : vehicle (Veh), URB597 1 mg/kg and URB602 10 mg/kg) ;
(b) the eﬀect of co-administration of FAAH and MAGL inhibitors in cocaine-conditioning (*** p<0.001 and ** p<0.01
compared to control groups without repeated cocaine co-administration) ; (c) the eﬀect of pretreatment with FAAH and MAGL
inhibitors during cocaine conditioning phase on cocaine-induced conditioned locomotion (CL) and behavioural sensitization
[cocaine sensitization (CS)] (*** p<0.001 and ** p<0.01 compared to CL groups) ; (d, e) the eﬀect of acute administration of
FAAH and MAGL inhibitors in the expression of an already acquired cocaine-induced CL and CS (*** p<0.001 and ** p<0.01
compared to Veh control group; ## p<0.01 and # p<0.05 compared to acute cocaine group). Values represent the mean¡S.E.M.
(n=8–10 per group).
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received acute administration of the MAGL inhibitor
(URB602) did not develop the sensitization response
(Fig. 5e).
Discussion
Growing evidence has established that the ECS acts
as a modulator of dopamine transmission in the
basal ganglia (Giuﬀrida & Piomelli, 2000 ; Rodriguez
de Fonseca et al. 1998). The development of endo-
cannabinoid degradation inhibitors has opened up
new alternatives for developing endocannabinoid-
based therapeutic strategies in dopamine-related dis-
orders (Ferna´ndez-Espejo et al. 2009; Piomelli,
2003). To illustrate the eﬀects of these inhibitors on
dopamine-mediated behaviours, we characterized the
behavioural performance of mice treated with QNP.
After QNP treatment, we subsequently studied phar-
macological eﬀects of endocannabinoid degradation
inhibitors on either QNP- or cocaine-induced behav-
iours. Results demonstrated the following : (1) similar
to rats, QNP produced a biphasic locomotion response
in mice (depression of locomotion followed by a
marked activation) and a dose-dependent increase
in stereotyped behaviours ; (2) inhibition of either
FAAH or MAGL abolished the increase in locomotion
induced by a high dose of QNP and suppressed the
induction of stereotyped behaviours ; ﬁnally, (3) inhi-
bition of both FAAH and MAGL aﬀected neither
psychomotor actions of cocaine nor the acquisition of
sensitization. However, blockage of 2-AG degradation
did reduce the expression of an already acquired
cocaine-induced sensitization. These results indicate
that inhibition of endocannabinoid degradation exerts
a potent suppression of dopamine D2/D3 receptor-
mediated stimulatory eﬀects on behaviour. However,
a very limited suppression of the maximal psycho-
stimulant eﬀects of cocaine was observed.
Activation of the dopamine D2/D3 receptor pro-
duces a marked decrease in motor activity by inhibit-
ing dopamine release from dopaminergic terminals
projecting to the basal ganglia. This eﬀect is mediated
through presynaptic dopamineD2/D3 receptors (Davis
et al. 1997). Despite this inhibitory eﬀect, stimulation
of post-synaptic dopamine D2/D3 receptors produces
enhanced locomotion and characteristic stereotyped
behaviours (including jumping, climbing and oral
movements). Thus, in rats a high dose of QNP pro-
duces a typical inhibitory component in behaviour,
followed by a temporary activation of locomotion and
stereotypies (Eilam et al. 1992; Rodriguez de Fonseca
et al. 1994). We characterized this response in C57Bl/6J
mice and found similar pharmacological eﬀects, which
have also been recently described (de Haas et al. in
press ; Jung & Shim, 2011). As depicted in Fig. 1, the
highest dose of QNP produced stimulation of move-
ment after its initial depressor eﬀect. The activation
of behaviour induced by QNP was transient and it
was accompanied by characteristic jumping and rear-
ing behaviours, but not grooming (a dopamine D1-
mediated behaviour ; Starr & Starr, 1986) as depicted
in Fig. 2. On the basis of these results, we selected
a dose of 1 mg/kg QNP to analyse the actions of the
endocannabinoid degradation inhibitors. These in-
hibitors were used at doses that did not result in motor
depressant eﬀects but are known to fully inhibit en-
zymatic activity (Fig. 3 ; Hohmann et al. 2005; Kathuria
et al. 2003; Luchicchi et al. 2010). When these inhibitors
were injected prior to QNP, its inhibitory eﬀect on
behavioural output was not aﬀected. This can be ex-
pected because dopamine neuron terminals (which
release dopamine) lack cannabinoid CB1 receptors
(Martin et al. 2008). However, pharmacological inhi-
bition of either FAAH or MAGL induced an attenu-
ation of behavioural stimulation elicited by QNP.
This attenuation indicates that the increase in AEA
and 2-AG is suﬃcient to abolish the stimulatory
component derived from dopamine D2/D3 receptor
activation. Similar ﬁndings have been described for
AEA transport inhibitor AM404 (Beltramo et al. 2000).
This ﬁnding might have important consequences
for therapeutics, particularly in Parkinson’s disease
and schizophrenia. For example, dyskinesia and
stereotyped behaviours associated with repeated
stimulation of dopamine D2 receptors appear after
long-term treatment with L-DOPA or dopamine agon-
ists in Parkinson’s disease or in the context of psy-
chostimulant abuse (Ferrer et al. 2003, 2007 ; Gorriti
et al. 1999). In both cases, stimulation of cannabinoid
CB1 receptors reduced their presence in animal models
(Ferrer et al. 2003, 2007 ; Gorriti et al. 1999). Regarding
schizophrenia, positive symptoms (i.e. delusion,
hallucination or behavioural disorganization) depend
on activation of dopamine D2 receptors and are
inversely correlated with cerebrospinal ﬂuid AEA
(Giuﬀrida et al. 2004). Hypothetically, an increase in
brain endocannabinoids resulting from pharmaco-
logical inhibition of FAAH and/or MAGL might
attenuate these symptoms.
Mechanistically, these eﬀects on dopamine D2/D3
receptor-mediated responses can be attributed to endo-
cannabinoids released through activation of D2/D3
receptors. Either AEA or 2-AG (released after dopa-
mine receptor activation) might act in several places
across the basal ganglia circuitry by engaging canna-
binoid CB1 receptors to reduce dopamine-induced
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behavioural activation. For instance, endocannabino-
ids can control pre-synaptic dopamine release (O’Neill
et al. 2009). This eﬀect most likely occurs through trans-
synaptic actions because cannabinoid CB1 receptors
are not present in dopaminergic neurons (Martin
et al. 2008). Additionally, endocannabinoids can
regulate dopamine receptor-mediated transmission.
Cannabinoid CB1 receptors are co-expressed with
either dopamine D1 or D2/D3 receptors in medium
spiny striatal neurons. Endocannabinoids can regulate
signalling at these receptors, most likely through
interaction with CB1 receptor dimers (formed with
dopamine D2/D3 receptors or adenosine A2A receptors
(Navarro et al. 2008)) or by regulating dopamine D2/D3
receptor availability (Crunelle et al. 2011). Finally,
endocannabinoids can exert their eﬀects by regulating
corticostriatal glutamatergic transmission (similar to
dopamine), therefore regulating dopamine-mediated
modulation of synaptic plasticity within the basal
ganglia (Adermark & Lovinger, 2007 ; Adermark et al.
2009; Gerdeman & Lovinger, 2001).
In the present study, we did not ﬁnd any eﬀects of
endocannabinoid degradation inhibitors on psycho-
stimulant eﬀects of cocaine (Fig. 5). Although the
role of endogenous cannabinoids as modulators of
dopamine transmission in addiction is clearly estab-
lished (Colombo et al. 2005; Ledent et al. 1999;
Maldonado & Rodriguez de Fonseca, 2002 ; Scherma
et al. 2008; Solinas et al. 2007, 2008), there is not a gen-
eral consensus about the functions of the ECS in co-
caine addiction (Arnold, 2005). Some studies indicate
that neither pharmacological antagonism nor deletion
of the CB1 receptor alters the acute rewarding eﬀects of
cocaine (Adamczyk et al. 2012; Lesscher et al. 2005;
Orio et al. 2009). However, there are other studies that
show the contrary (Li et al. 2009; Soria et al. 2005; Xi
et al. 2008). CB1 receptors appear to be involved in the
association of cocaine reward with environmental
cues, reinstatement of cocaine self-administration and
acquisition of behavioural sensitization (Adamczyk
et al. 2012; de Vries et al. 2001; Gerdeman et al. 2008).
Additionally, a new role for cannabinoid CB2 receptors
in cocaine addiction is emerging (Xi et al. 2011). In the
present study, inhibition of FAAH or MAGL aﬀected
neither acute psychomotor actions of cocaine nor
the acquisition of behavioural sensitization or the ex-
pression of conditioned locomotion. Because cocaine
is not a selective blocker of dopamine uptake, we can
hypothesize that the psychostimulant proﬁle of cocaine
may be independent of endocannabinoid modulation
of dopaminergic transmission. In this sense, it is im-
portant to note that the eﬀects of cocaine on serotonin
transporters are suﬃcient to sustain the rewarding
eﬀects of the psychostimulant in dopamine-deﬁcient
mice (Hnasko et al. 2007). Thus, it is feasible to hypoth-
esize that an increase in endocannabinoid availability
by inhibiting endocannabinoid degradation may not
be suﬃcient to attenuate psychostimulant actions of
cocaine.
Finally, we observed a MAGL-induced decrease in
the expression of an already acquired cocaine-induced
sensitization. Because sensitization involves eﬀects of
external associative cues, this pharmacological eﬀect
could be associatedwith those described for other ECS-
dependent associative responses in Pavlovian con-
ditioning protocolswith cocaine (Adamczyk et al. 2012;
de Vries et al ; 2001 ; Gerdeman et al. 2008). However,
the speciﬁcity of our observation, together with the
lack of eﬀects of endocannabinoid degradation
inhibitors on conditioned locomotion, makes it very
diﬃcult to draw conclusions about the role of this
class of drugs in Pavlovian conditioning. Whether this
selective attenuation of behavioural sensitization re-
ﬂects a state-dependent change in dopamine trans-
mission induced by cocaine (Chefer & Shippenberg,
2002), diﬀerential adaptations in 2-AG signalling or
2-AG selective actions on striatal plasticity associated
with repeated cocaine exposure remains to be deter-
mined.
In summary, the present study demonstrates that
inhibition of endocannabinoid degradation attenuates
dopamine D2/D3 receptor-mediated behavioural acti-
vation. This ﬁnding might be relevant for neuro-
psychopharmacological therapies for dopamine-
related disorders.
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